Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Cebrián, Rubén; Rodríguez-Cabezas, M. Elena; Martín‐Escolano, Rubén; Rubiño, Susana; Garrido-Barros, María; Montalbán-López, Manuel; Rosales, María J.; Sánchez‐Moreno, Manuel; Valdivia, Eva; Martínez‐Bueno, Manuel; Marı́n, Clotilde; Gálvez, Júlio; Maqueda, Mercedes

doi:10.1016/j.jare.2019.06.003

Cited by 53 publications

(44 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is interesting to note that this bacteriocin also did not induce any skin sensitization or allergic contact dermatitis after topical application (Cebrián et al . 2019 ). Additionally, OG716, a derivative of mutacin 1140, which is considered as a potential candidate for CDAD treatment, has shown no toxicity or side effects upon oral administration in Golden Syrian Hamster; hence, it may progress toward clinical development (Pulse et al .…”

Section: Evaluation Of Bacteriocin Safetymentioning

confidence: 99%

Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations

Soltani

Hammami

Cotter

et al. 2020

FEMS Microbiology Reviews

364

246

View full text Add to dashboard Cite

In recent decades, bacteriocins have received substantial attention as antimicrobial compounds. Although bacteriocins have been predominantly exploited as food preservatives, they are now receiving increased attention as potential clinical antimicrobials and as possible immune-modulating agents. Infections caused by antibiotic-resistant bacteria have been declared as a global threat to public health. Bacteriocins represent a potential solution to this worldwide threat due to their broad or narrow spectrum activity against antibiotic-resistant bacteria. Notably, despite their role in food safety as natural alternatives to chemical preservatives, nisin remains the only bacteriocin legally approved by regulatory agencies as a food preservative. Moreover, insufficient data on the safety and toxicity of bacteriocins represents a barrier against the more widespread use of bacteriocins by the food and medical industry. Here we focus on the most recent trends relating to the application of bacteriocins, their toxicity and impacts.

show abstract

Section: Evaluation Of Bacteriocin Safetymentioning

confidence: 99%

Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations

Soltani

Hammami

Cotter

et al. 2020

FEMS Microbiology Reviews

364

246

View full text Add to dashboard Cite

show abstract

“…Similar synergistic behavior has been observed with other bacteriocins used in combination with antibiotics against clinical and veterinary pathogens [ 39 ]. These data, together with the safety of AS-48, lacking of toxic effects demonstrated in in vivo and in vivo assays [ 24 ], strongly support this bacteriocin as a leading compound to fight enterococcal infections. Moreover, its mechanism of action reduces the appearance of resistance.…”

Section: Discussionmentioning

confidence: 97%

“…AS-48 is a circular, well-characterized [ 15 , 35 ] and safe [ 24 ] bacteriocin with a proven, broad potential in the food industry and potential health applications. This cationic and amphipathic peptide has a bactericidal effect inhibiting the growth of several pathogenic Gram-positive bacteria, such as Staphylococcus aureus [ 23 ], Cutibacterium acnes (causing cell death and impaired biofilm formation) [ 19 ], or even Mycobacterium tuberculosis [ 36 ], among others.…”

Section: Discussionmentioning

confidence: 99%

“…AS-48 from concentrated supernatants of the producer strain E. faecalis UGRA10 was purified to homogeneity (up to 95% purity) by cation exchange (Sepharose BigBeads) (GE Healthcare, Madrid, Spain), followed by reversed-phase, high-performance liquid chromatography (RP-HPLC) and monitoring using antimicrobial activity tests as described elsewhere [ 24 ]. The purified samples were aliquoted and freeze-dried for storage at 4 °C under vacuum.…”

Section: Methodsmentioning

confidence: 99%

“…In addition, a potent trypanocidal activity has been recently described [ 18 , 20 , 21 ]. Moreover, AS-48 has not shown any remarkable toxicity in vivo or in vitro after a preclinical characterization of the molecule, indicating the safety of the molecule for clinical application [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci

et al. 2020

Self Cite

View full text Add to dashboard Cite

The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, Enterococcus strains isolated from UTIs were characterized, showing that the majority were E. faecalis and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections.

show abstract

Nanofiber Peptides for Bacterial Trapping: A Novel Approach to Antibiotic Alternatives in Wound Infections

Yang,

Wang,

Wang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The pervasive employment of antibiotics has engendered the advent of drug‐resistant bacteria, imperiling the well‐being and health of both humans and animals. Infections precipitated by such multi‐resistant bacteria, especially those induced by methicillin‐resistant Staphylococcus aureus, pervade hospital settings, constituting a grave menace to patient vitality. Antimicrobial peptides have garnered considerable attention as a potent countermeasure against multi‐drug resistant bacteria. In preceding research endeavors, we identified an insect‐derived antimicrobial peptide that, while possessing antimicrobial attributes, manifested suboptimal efficacy against drug‐resistant gram‐positive bacteria. To ameliorate this issue, we enhanced the antimicrobial capabilities of the initial β‐hairpin AMPs by substituting the structural sequence of the original AMPs with variant lengths of hydrophobic amino acid‐hydrophilic amino acid repeat units. Throughout this endeavor, we have identified a number of peptides that possess highly effective antibacterial characteristics against a wide range of bacteria. Additionally, some of these peptides have the ability to self‐assemble into nanofibers, which then build networks in a distinctive manner to capture bacteria. Consequently, they represent prospective antibiotic alternatives for addressing wound infections engendered by drug‐resistant bacteria.This article is protected by copyright. All rights reserved

show abstract

Preclinical studies of toxicity and safety of the AS-48 bacteriocin

Abstract: Graphical abstract

Cited by 53 publications

References 58 publications

Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations

Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations

Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci

Nanofiber Peptides for Bacterial Trapping: A Novel Approach to Antibiotic Alternatives in Wound Infections

Contact Info

Product

Resources

About